Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
CA.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.83NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.40NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.160.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
AY.4.2.4 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.161NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.75NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.411NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.217NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.35NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.17 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17890.7US
B.1.1.41NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.527NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
C.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.500NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.147NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.487NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.68NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-6672.85US
B.1.1.121NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AA.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-17121.6US
AS.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.115NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.127.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.88NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AP.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.98.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.13.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.34.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.124.1.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.203NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.8.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.236NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.33NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XQNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.395NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.120.2.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.416.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.532NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.408NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XHNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.168NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.39NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.57NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AH.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.289NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.365NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.252NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used